JP7005007B2 - 固体形態 - Google Patents

固体形態 Download PDF

Info

Publication number
JP7005007B2
JP7005007B2 JP2017557899A JP2017557899A JP7005007B2 JP 7005007 B2 JP7005007 B2 JP 7005007B2 JP 2017557899 A JP2017557899 A JP 2017557899A JP 2017557899 A JP2017557899 A JP 2017557899A JP 7005007 B2 JP7005007 B2 JP 7005007B2
Authority
JP
Japan
Prior art keywords
xrpd
diffraction pattern
compound
particular embodiment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516883A (ja
JP2018516883A5 (enExample
Inventor
ラルフ ディオドネ，
ウルス シュヴィッター，
レネ トルッサルディ，
Original Assignee
オリソン ヘノミクス エセ． アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリソン ヘノミクス エセ． アー． filed Critical オリソン ヘノミクス エセ． アー．
Publication of JP2018516883A publication Critical patent/JP2018516883A/ja
Publication of JP2018516883A5 publication Critical patent/JP2018516883A5/ja
Priority to JP2021060013A priority Critical patent/JP2021119136A/ja
Application granted granted Critical
Publication of JP7005007B2 publication Critical patent/JP7005007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017557899A 2015-05-06 2016-05-02 固体形態 Active JP7005007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021060013A JP2021119136A (ja) 2015-05-06 2021-03-31 固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166641.9A EP3090998A1 (en) 2015-05-06 2015-05-06 Solid forms
EP15166641.9 2015-05-06
PCT/EP2016/059726 WO2016177656A1 (en) 2015-05-06 2016-05-02 Solid forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021060013A Division JP2021119136A (ja) 2015-05-06 2021-03-31 固体形態

Publications (3)

Publication Number Publication Date
JP2018516883A JP2018516883A (ja) 2018-06-28
JP2018516883A5 JP2018516883A5 (enExample) 2019-06-06
JP7005007B2 true JP7005007B2 (ja) 2022-02-04

Family

ID=53039825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017557899A Active JP7005007B2 (ja) 2015-05-06 2016-05-02 固体形態
JP2021060013A Pending JP2021119136A (ja) 2015-05-06 2021-03-31 固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021060013A Pending JP2021119136A (ja) 2015-05-06 2021-03-31 固体形態

Country Status (15)

Country Link
US (1) US10221125B2 (enExample)
EP (2) EP3090998A1 (enExample)
JP (2) JP7005007B2 (enExample)
KR (1) KR102666390B1 (enExample)
CN (1) CN107735394B (enExample)
AR (1) AR104505A1 (enExample)
AU (1) AU2016259054B2 (enExample)
BR (1) BR112017023740B1 (enExample)
CA (1) CA2984203C (enExample)
ES (1) ES2969970T3 (enExample)
HU (1) HUE065558T2 (enExample)
IL (1) IL255194B (enExample)
MX (1) MX378732B (enExample)
PL (1) PL3292100T3 (enExample)
WO (1) WO2016177656A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CA3253937A1 (en) 2016-03-15 2025-03-04 Oryzon Genomics, S.A. Combinations of Lysine-Specific Demethylase 1 Inhibitors for the Treatment of Hematological Maligna
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
US10780081B2 (en) 2016-06-10 2020-09-22 Oryzon Genomics, S.A. Method of treating multiple sclerosis employing a LSD1-inhibitor
KR102685898B1 (ko) 2017-08-03 2024-07-19 오리존 지노믹스 에스.에이. 행동 변경 치료 방법
CN112040934A (zh) * 2018-05-04 2020-12-04 奥莱松基因组股份有限公司 稳定的药物制剂
AU2020242302B2 (en) 2019-03-20 2025-10-30 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
AU2020249493B2 (en) * 2019-03-25 2025-08-28 Oryzon Genomics, S.A. Combinations of iadademstat for cancer therapy
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
EP4319732A1 (en) 2021-04-08 2024-02-14 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502335A (ja) 2011-10-20 2015-01-22 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741086B2 (en) 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
DK1704859T3 (da) 2005-02-18 2010-11-22 Universitaetsklinikum Freiburg Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1)
CN101410367A (zh) 2005-08-10 2009-04-15 约翰·霍普金斯大学 多胺用在抗寄生虫与抗癌治疗学以及作为赖氨酸-特异性脱甲基酶抑制剂
US20110092601A1 (en) 2007-04-13 2011-04-21 The Johns Hopkins University Lysine-specific demethylase inhibitors
EP2317992A2 (en) 2008-07-24 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
US9708255B2 (en) 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011113005A2 (en) 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo)
WO2011131697A1 (en) 2010-04-19 2011-10-27 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EA022459B1 (ru) 2010-04-20 2016-01-29 Университа' Дельи Студи Ди Рома "Ла Сапиенца" Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
JP5813855B2 (ja) 2011-03-25 2015-11-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｌｓｄ１阻害剤としてのシクロプロピルアミン
EP2750671A2 (en) 2011-05-19 2014-07-09 Oryzon Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
WO2012156531A2 (en) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017060319A1 (en) 2015-10-09 2017-04-13 F. Hoffmann-La Roche Ag Gene expression biomarkers for personalized cancer care to epigenetic modifying agents
CA3253937A1 (en) 2016-03-15 2025-03-04 Oryzon Genomics, S.A. Combinations of Lysine-Specific Demethylase 1 Inhibitors for the Treatment of Hematological Maligna
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
US20190256929A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502335A (ja) 2011-10-20 2015-01-22 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｍｉｎｏ Ｒ．Ｃａｉｒａ，Ｃｒｙｓｔａｌｌｉｎｅ Ｐｏｌｙｍｏｒｐｈｉｓｍ ｏｆ Ｏｒｇａｎｉｃ Ｃｏｍｐｏｕｎｄｓ，Ｔｏｐｉｃｓ ｉｎ Ｃｕｒｒｅｎｔ Ｃｈｅｍｉｓｔｒｙ，ドイツ，Ｓｐｒｉｎｇｅｒ，１９９８年，Ｖｏｌ．１９８，ｐｐ．１６３－２０８，ＵＲＬ，ｈｔｔｐｓ：／／ｌｉｎｋ．ｓｐｒｉｎｇｅｒ．ｃｏｍ／ｃｈａｐｔｅｒ／１０．１００７／３－５４０－６９１７８－２＿５

Also Published As

Publication number Publication date
AU2016259054B2 (en) 2020-08-13
BR112017023740A2 (pt) 2018-07-17
KR20180022660A (ko) 2018-03-06
CN107735394A (zh) 2018-02-23
US10221125B2 (en) 2019-03-05
ES2969970T3 (es) 2024-05-23
HK1252089A1 (en) 2019-05-17
JP2018516883A (ja) 2018-06-28
CA2984203C (en) 2024-07-02
EP3292100C0 (en) 2023-11-15
CA2984203A1 (en) 2016-11-10
AU2016259054A1 (en) 2017-11-16
BR112017023740B1 (pt) 2023-11-07
AR104505A1 (es) 2017-07-26
EP3292100A1 (en) 2018-03-14
US20180086692A1 (en) 2018-03-29
MX378732B (es) 2025-03-11
MX2017014035A (es) 2018-03-01
IL255194B (en) 2021-03-25
IL255194A0 (en) 2017-12-31
EP3090998A1 (en) 2016-11-09
JP2021119136A (ja) 2021-08-12
PL3292100T3 (pl) 2024-04-22
HK1245235A1 (zh) 2018-08-24
HUE065558T2 (hu) 2024-06-28
WO2016177656A1 (en) 2016-11-10
CN107735394B (zh) 2021-11-02
EP3292100B1 (en) 2023-11-15
KR102666390B1 (ko) 2024-05-21

Similar Documents

Publication Publication Date Title
JP7005007B2 (ja) 固体形態
WO2008068615A1 (en) Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
ES2922158T3 (es) Compuestos cristalinos
US7642353B2 (en) Process of making crystalline aripiprazole
CN1714098A (zh) β－L－2'－脱氧胸苷的结晶形及非晶形
ES2873828T3 (es) Preparación y cristalización innovadoras de iosimenol
WO2023096954A9 (en) Solid state forms of nirogacestat salts
KR20220148860A (ko) 2-[(4s)-8-플루오로-2-[4-(3-메톡시페닐)피페라진-1-일]-3-[2-메톡시-5-(트리플루오로메틸)페닐]-4h-퀴나졸린-4-일]아세트산의 칼륨 염
HK1252089B (en) Solid forms
HK1245235B (zh) 固体形式
WO2023164255A1 (en) Crystalline forms of trilaciclib and trilaciclib salts
JP5651271B2 (ja) デニブリン二塩酸塩
CN108137626B (zh) Fosnetupitant的晶型
WO2013082302A1 (en) Agomelatine-urea complex and crystalline forms thereof
EP2507250A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
JP5197955B2 (ja) 結晶性デキスロキシグルミドの製造法
HK40108981A (zh) 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
US20110313044A1 (en) Polymorphs of Suberoylanilide Hydroxamic Acid
WO2025201325A1 (zh) 4-[3-(环丙基甲氧基)-4-(二氟甲氧基)苯乙基]吡啶-2(1h)-酮的固体形式及其制备方法
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
WO2010067136A1 (en) Novel crystalline forms
WO2021028678A1 (en) Polymorph of venetoclax and method for preparing the polymorph
JP2007302560A (ja) 医薬化合物
JP2007302559A (ja) 医薬化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210331

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210427

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210427

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20210525

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20210709

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210713

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211026

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211124

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211223

R150 Certificate of patent or registration of utility model

Ref document number: 7005007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250